Thereza Christina Monteiro de Lima

Thereza Christina Monteiro de Lima

Auto-generated profile, based on publicly available information

Thereza Christina Monteiro de Lima

Department of Pharmacology, Center of Biological Sciences, Federal University of Santa Catarina, Florianópolis, SC 88049-900, Brazil

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Neuropeptides
Verified
Journal Article
Open access
RTR.O. Tasan
R.O. Tasan
DVD. Verma
D. Verma
JWJ. Wood
J. Wood
GLG. Lach
G. Lach
BHB. Hörmer
B. Hörmer
GSG. Sperk
G. Sperk
While anxiety disorders are the brain disorders with the highest prevalence and constitute a major burden for society, a considerable number of affected people are still treated insufficiently. Thus, in an attempt to identify potential new anxiolytic drug targets, neuropeptides have gained considerable attention in recent years. Compared to classical neurotransmitters they often have a regionally restricted distribution and may bind to several distinct receptor subtypes. Neuropeptide Y (NPY) is a highly conserved neuropeptide that is specifically concentrated in limbic brain areas and signals via at least 5 different G-protein-coupled receptors. It is involved in a variety of physiological processes including the modulation of emotional-affective behaviors. An anxiolytic and stress-reducing property of NPY is supported by many preclinical studies. Whether NPY may also interact with processing of learned fear and fear extinction is comparatively unknown. However, this has considerable relevance since pathological, inappropriate and generalized fear expression and impaired fear extinction are hallmarks of human post-traumatic stress disorder and a major reason for its treatment-resistance. Recent evidence from different laboratories emphasizes a fear-reducing role of NPY, predominantly mediated by exogenous NPY acting on Y1 receptors. Since a reduction of fear expression was also observed in Y1 receptor knockout mice, other Y receptors may be equally important. By acting on Y2 receptors, NPY promotes fear extinction and generates a long-term suppression of fear, two important preconditions that could support cognitive behavioral therapies in human patients. A similar effect has been demonstrated for the closely related pancreatic polypeptide (PP) when acting on Y4 receptors. Preliminary evidence suggests that NPY modulates fear in particular by activation of Y1 and Y2 receptors in the basolateral and central amygdala, respectively. In the basolateral amygdala, NPY signaling activates inhibitory G protein-coupled inwardly-rectifying potassium channels or suppresses hyperpolarization-induced I(h) currents in a Y1 receptor-dependent fashion, favoring a general suppression of neuronal activity. A more complex situation has been described for the central extended amygdala, where NPY reduces the frequency of inhibitory and excitatory postsynaptic currents. In particular the inhibition of long-range central amygdala output neurons may result in a Y2 receptor-dependent suppression of fear. The role of NPY in processes of learned fear and fear extinction is, however, only beginning to emerge, and multiple questions regarding the relevance of endogenous NPY and different receptor subtypes remain elusive. Y2 receptors may be of particular interest for future studies, since they are the most prominent Y receptor subtype in the human brain and thus among the most promising therapeutic drug targets when translating preclinical evidence to potential new therapies for human anxiety disorders.

1 September 1996 in European Journal of Pharmacology
Verified
Journal Article
Closed access
RTRaquel M. Teixeira
Raquel M. Teixeira
ASAdair R.S. Santos
Adair R.S. Santos
SRSandro J. Ribeiro
Sandro J. Ribeiro
JCJoão B. Calixto
João B. Calixto
GRGiles A. Rae
Giles A. Rae
TLThereza C.M. De Lima
Thereza C.M. De Lima

1 August 2012 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
PGPablinny Moreira Galdino
Pablinny Moreira Galdino
MNMarcus Vinícius Mariano Nascimento
Marcus Vinícius Mariano Nascimento
IFIziara Ferreira Florentino
Iziara Ferreira Florentino
RLRoberta Campos Lino
Roberta Campos Lino
JFJames Oluwagbamigbe Fajemiroye
James Oluwagbamigbe Fajemiroye
ECElson Alves Costa
Elson Alves Costa

14 May 2003 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
EGElaine Gavioli
Elaine Gavioli
GMG. Marzola
G. Marzola
RGRemo Guerrini
Remo Guerrini
Rosalia BertorelliRosalia Bertorelli
Rosalia Bertorelli
SZS. Zucchini
S. Zucchini
GCG. Calo
G. Calo

1 May 2013 in Behavioural Brain Research
Verified
Journal Article
Closed access
VSVanessa V. dos Santos
Vanessa V. dos Santos
DSDanúbia B. Santos
Danúbia B. Santos
GLGilliard Lach
Gilliard Lach
Ana Lúcia S. RodriguesAna Lúcia S. Rodrigues
Ana Lúcia S. Rodrigues
Marcelo FarinaMarcelo Farina
Marcelo Farina
RPRui Daniel Prediger
Rui Daniel Prediger

1 May 2008 in Behavioural Brain Research
Verified
Journal Article
Closed access
MCMiguel Coleta
Miguel Coleta
Maria Graça CamposMaria Graça Campos
Maria Graça Campos
MCMaria Dulce Cotrim
Maria Dulce Cotrim
TLThereza Christina M. de Lima
Thereza Christina M. de Lima
ACAntónio Proença da Cunha
António Proença da Cunha